ETF 日报 2025.11.19 市场概况： ◼ 今日 A 股上证综指上涨 0.18%，收于 3946.74 点，深证成指下跌 0.00%，收于 13080.09 点，创业板指上涨 0.25%，收于 3076.85 点， 两市 A 股成交金额为 17428 亿元。涨幅靠前的行业有：有色金属 （2.39%）、石油石化（1.67%）、国防军工（1.11%），跌幅靠前的行 业有：综合（-3.08%）、房地产（-2.09%）、传媒（-1.72%）。 股票 ETF： ◼ 今日成交金额靠前的股票 ETF 为：华夏中证 A500ETF 上涨 0.17%， 贴水率为 0.24%；华泰柏瑞中证 A500ETF 上涨 0.16%，贴水率为 0.29%；国泰中证 A500ETF 上涨 0.17%，贴水率为 0.31%。 债券 ETF： ◼ 今日成交金额靠前的债券 ETF 为：海富通中证短融 ETF 上涨 0.01%， 贴水率为 0.00%；华夏上证基准做市国债 ETF 下跌 0.06%，贴水率 为-0.01%；易方达中证 AAA 科技创新公司债 ETF 上涨 0.02%，贴水 率为-0.25%。 2025 年 11 月 19 日 ...

Core Viewpoint - As of November 14, the total margin balance for ETFs in the Shanghai and Shenzhen markets is 118.423 billion yuan, showing a decrease of 0.311 billion yuan from the previous trading day [1] Summary by Category ETF Margin Balance - The ETF financing balance is 110.189 billion yuan, down by 0.103 billion yuan from the previous trading day [1] - The ETF margin short balance is 8.234 billion yuan, decreasing by 0.208 billion yuan compared to the previous trading day [1] Net Buy Activity - On November 14, 248 ETFs experienced net financing purchases, with the top net purchase being the Huaxia Hang Seng Internet Technology ETF, which saw a net buy of 0.174 billion yuan [1] - Other ETFs with significant net buy amounts include the E Fund ChiNext ETF, E Fund CSI Overseas Internet ETF, GF CSI Hong Kong Innovative Medicine ETF, GF Shanghai Gold ETF, and Guotai Junan CSI A500 ETF [1]

Core Insights - The QDII funds market has shown strong performance in the first ten months of the year, with 95.1% of the 650 comparable funds reporting net value increases, while only 32 funds experienced declines [1] Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hong Kong Advantage Selected Mixed A and C, both achieving returns of 117.54% and 117.53% respectively [1] - A total of 10 QDII funds recorded gains exceeding 78%, with E Fund's Global Growth Selected Mixed A and C (USD and RMB) each surpassing 83% [2][3] - The leading funds in the innovation drug sector have significantly contributed to the overall performance, with notable funds like the GF CSI Hong Kong Innovation Drug ETF and others achieving returns between 78.11% and 88.09% [3] Investment Focus - The investment strategy of the top-performing funds emphasizes sectors such as innovative pharmaceuticals and high-barrier medical equipment, targeting companies with global competitiveness and growth potential [1][3] - The top holdings of the leading funds include major players in the biotech and pharmaceutical industries, such as TSMC, NVIDIA, and Alibaba [2][3] Market Trends - The innovation drug sector has rebounded, leading to a broad increase in related stocks, which has positively impacted the performance of funds heavily invested in this area [1][3] - Conversely, funds focused on oil and gas, as well as real estate, have underperformed, indicating a sector rotation within the QDII market [4]

Core Insights - The innovative drug-themed ETFs have performed well this year, with many funds achieving positive returns and a significant increase in overall scale, surpassing 100 billion yuan as of November 7 [1][2] Performance Overview - As of now, all 27 innovative drug-themed ETFs have realized net value growth this year, with 9 funds showing a net value growth rate exceeding 50%, and several products maintaining growth rates above 80% [1] - Notable funds include Wanji Zhongzheng Hong Kong Stock Connect Innovative Drug ETF, GF Zhongzheng Hong Kong Innovative Drug ETF, and Yinhua Guozheng Hong Kong Stock Connect Innovative Drug ETF [1] Fund Size and Rankings - Three products have surpassed 10 billion yuan in scale, with GF Hong Kong Innovative Drug ETF leading at 24.636 billion yuan, followed by Huitianfu Hong Kong Stock Connect Innovative Drug ETF at 21.719 billion yuan, and Yinhua Innovative Drug ETF at 13.187 billion yuan [2] - Ten additional products maintain scales between 1 billion and 8 billion yuan [2] Market Drivers - The expansion of innovative drug-themed ETFs is driven by multiple factors, including policy benefits, continuous institutional investment, improved liquidity, and the strengthening fundamentals of innovative drug companies [2] - The valuation of the innovative drug sector has recovered from previous lows, further stimulating investor interest [2] Industry Outlook - The Chinese pharmaceutical industry has completed a transition to new growth drivers, with innovative drugs opening new growth avenues for Chinese pharmaceutical companies [2] - The number and value of outbound licensing transactions for Chinese innovative drugs have reached new highs, indicating a positive outlook for the industry's prosperity [2] - The innovative drug sector is expected to enter a fundamental catalyst period, with advantages in patient resources, research and development costs, clinical efficiency, and policy support [2]

Core Viewpoint - As of November 3, the total margin balance of ETFs in the Shanghai and Shenzhen markets reached 121.654 billion yuan, reflecting an increase of 2.722 billion yuan from the previous trading day [1] Group 1: ETF Financing and Margin Balances - The ETF financing balance stood at 113.527 billion yuan, up by 2.542 billion yuan compared to the previous trading day [1] - The ETF margin short balance was recorded at 8.127 billion yuan, which is an increase of 180 million yuan from the previous trading day [1] Group 2: Net Inflows in ETFs - On November 3, 280 ETFs experienced net financing inflows, with the top net inflow being the Fortune China Government Bond ETF (7-10 years) at 1.487 billion yuan [1] - Other ETFs with significant net inflows included the Bosera China Government Bond ETF (0-3 years), the Guotai Asset 5-Year Government Bond ETF, and several others focused on innovative pharmaceuticals and technology sectors [1]

Report Summary 1. Market Overview - On October 31, 2025, the Shanghai Composite Index fell 0.81% to 3954.79 points, the Shenzhen Component Index dropped 1.14% to 13378.21 points, and the ChiNext Index declined 2.31% to 3187.53 points. The total trading volume of A - shares in the two markets was 2350.1 billion yuan. The top - performing sectors were Medicine and Biology (2.42%), Media (2.39%), and Commerce and Retail (2.08%), while the worst - performing sectors were Communication (-4.07%), Electronics (-3.06%), and Non - ferrous Metals (-2.03%) [2][6] 2. Stock ETFs - The top - trading - volume stock ETFs on this day were: Huatai - Peregrine CSI 300 ETF, which fell 1.39% with a premium rate of -1.38%; ChinaAMC CSI A500 ETF, down 1.10% with a premium rate of -1.09%; and ChinaAMC SSE STAR Market 50 ETF, dropped 3.06% with a premium rate of -3.02% [3][7] 3. Bond ETFs - The top - trading - volume bond ETFs were: Haifutong CSI Short - term Financing Bond ETF, up 0.01% with a premium rate of 0.01%; ChinaAMC CSI AAA Science and Technology Innovation Corporate Bond ETF, rose 0.12% with a premium rate of -0.09%; and Bosera CSI Convertible and Exchangeable Bond ETF, increased 0.07% with a premium rate of 0.00% [4][9] 4. Gold ETFs - Gold AU9999 rose 1.61% and Shanghai Gold increased 1.26%. The top - trading - volume gold ETFs were: Huaan Gold ETF, up 1.03% with a premium rate of 1.37%; Bosera Gold ETF, rose 1.14% with a premium rate of 1.29%; and E Fund Gold ETF, increased 1.09% with a premium rate of 1.28% [12] 5. Commodity Futures ETFs - Dacheng Non - ferrous Metals Futures ETF fell 0.61% with a premium rate of -0.99%; ChinaAMC Feed Soybean Meal Futures ETF rose 0.36% with a premium rate of 2.23%; and CCB Yisheng Zhengzhou Commodity Exchange Energy and Chemical Futures ETF dropped 0.40% with a premium rate of -1.24% [15] 6. Cross - border ETFs - The previous trading day, the Dow Jones Industrial Average fell 0.23%, the Nasdaq dropped 1.57%, the S&P 500 declined 0.99%, and the German DAX fell 0.02%. On this day, the Hang Seng Index dropped 1.43% and the Hang Seng China Enterprises Index fell 1.91%. The top - trading - volume cross - border ETFs were: E Fund CSI Hong Kong Securities Investment Theme ETF, down 2.34% with a premium rate of -2.53%; GF CSI Hong Kong Innovative Drugs ETF, up 5.12% with a premium rate of 4.29%; and Huatai - Peregrine Hang Seng Technology ETF, dropped 1.25% with a premium rate of -1.69% [17] 7. Money Market ETFs - The top - trading - volume money market ETFs were Huabao Tianyi ETF, Yin Hua Rili ETF, and CCB Tianyi Money Market ETF [19]

Core Viewpoint - As of October 29, the total margin balance for ETFs in the Shanghai and Shenzhen markets reached 121.534 billion yuan, reflecting an increase of 0.524 billion yuan from the previous trading day [1] Summary by Category ETF Margin Balance - The ETF financing balance was 113.243 billion yuan, up by 0.436 billion yuan from the previous trading day [1] - The ETF margin short balance stood at 8.291 billion yuan, increasing by 0.088 billion yuan compared to the previous trading day [1] Net Buy Activity - On October 29, 291 ETFs experienced net financing purchases, with the top net purchase being the E Fund CSI Hong Kong Securities Investment Theme ETF, which saw a net inflow of 0.253 billion yuan [1] - Other ETFs with significant net financing purchases included the Guotai CSI All Share Communication Equipment ETF, Pengyang 30-Year Treasury Bond ETF, and others [1]

Core Viewpoint - As of October 23, the total margin balance for ETFs in the Shanghai and Shenzhen markets reached 119.55 billion yuan, reflecting an increase of 1.365 billion yuan from the previous trading day [1] Group 1: ETF Financing and Margin Data - The ETF financing balance stood at 111.65 billion yuan, up by 1.181 billion yuan compared to the previous trading day [1] - The ETF margin short balance was 7.905 billion yuan, which increased by 184 million yuan from the previous trading day [1] Group 2: Top Performing ETFs - On October 23, 281 ETFs experienced net financing inflows, with the Pengyang 30-Year Government Bond ETF leading with a net inflow of 165 million yuan [1] - Other notable ETFs with significant net financing inflows included the Huaxia Hang Seng Technology ETF, GF CSI Hong Kong Innovative Medicine ETF, Huaan Gold ETF, and several others [1]

Core Viewpoint - As of October 14, the total margin balance for ETFs in the Shanghai and Shenzhen markets reached 116.587 billion yuan, reflecting an increase of 0.952 billion yuan from the previous trading day [1] Summary by Category ETF Margin Balance - The ETF financing balance was 108.785 billion yuan, up by 0.794 billion yuan from the previous trading day [1] - The ETF margin short balance was 7.802 billion yuan, increasing by 0.158 billion yuan compared to the previous trading day [1] Net Buy Activity - On October 14, 232 ETFs experienced net financing purchases, with the top net purchase being the Fortune China Government Bond 7-10 Year Policy Financial Bond ETF, which saw a net buy of 0.154 billion yuan [1] - Other ETFs with significant net purchases included the Guolian An Zhongzheng All-Index Semiconductor ETF, Huatai-PB Hang Seng Technology ETF, Huaxia Zhongzheng Robot ETF, GF Zhongzheng Hong Kong Innovative Drug ETF, Huitianfu Zhongzheng Major Consumption ETF, and Huaxia Nasdaq 100 ETF [1]

Core Insights - In the first three quarters of this year, 624 out of 650 comparable QDII funds saw an increase in net value, representing a 96% success rate, while 26 funds experienced a decline [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers achieving returns exceeding 155% [1][2] - The top-performing QDII funds include Huatai-PB Hong Kong Advantage Selected Mixed Fund A and C, both achieving returns of 155.14% and 155.09% respectively [1] Fund Performance - 13 QDII funds recorded gains over 100%, with four from E Fund Management, including E Fund Global Pharmaceutical Industry Mixed Fund A and C, all surpassing 102% [2] - The top holdings of these funds include companies like Innovent Biologics, I-Mab Biopharma, and others in the innovative drug sector [2][3] - Other notable funds with over 100% returns include GF CSI Hong Kong Innovative Drug ETF and ICBC New Economy Mixed Fund, with respective gains of 112.80% and 104.12% [3] Fund Management - The current fund manager for Huatai-PB Hong Kong Advantage Selected Mixed Fund is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - E Fund's funds are managed by Yang Zhenxiao, who has a background in investment management and industry research [3] Sector Analysis - The innovative drug sector has shown strong performance, contributing to the significant gains of various QDII funds [3][4] - Funds with poor performance are primarily those focused on real estate and oil & gas sectors, as well as those tracking the S&P 500 healthcare index [5]